cl-user
#41
Looks like low neutrophil and low ALP is the way to go once the other stuff is normal:
As expected, clinical indicators of chronic
disease risk (for example, glucose, cholesterol) were uniformly normal
for strongly healthy patients (as they are free from chronic disease
risk) and therefore did not account for the additional variability in
*their longevity scores.
In contrast to these indicators, we observed low
neutrophil, low ALP and a high ratio between microcytic and hypochromatic
red blood cells as indicative of a high longevity score in strongly
*healthy individuals.
Interestingly, for some clinical markers, medium
levels were associated with a high longevity score in strongly healthy
individuals, even though their even higher levels were associated with
chronic disease risk. For example, medium (but not low) body mass
index (BMI), creatinine in the 60th to 50th centile (but not lower) or
liver enzymes (ALT) at the 60th percentile (but not lower) were all correlated
with a high longevity score, while their much higher values were
linked with chronic disease risk.
2 Likes
AnUser
#42
I’ve seen on reddit that the CETP inhibitor will not be expensive and will release in 2025, big if true, but somehow I doubt it.
Neo
#43
Then Phase 3 trials most close to readouts indeed, or perhaps the data is so strong they will end early?
Here’s @ConquerAging latest video on this data : Cystatin-C as a key indicator of aging
Cystatin-C:
<0.7 = ~100% survival 18 years
1.08 = 50% survival 18 years
Cystatin-C largest indicator of biological age after chron age and sex.
2 Likes
